Medtronic (Dublin) made a huge splash in the drug-eluting stent (DES) space Thursday, when the med-tech giant revealed that it would begin its Resolute Onyx Clinical program in the U.S. for patients who have coronary artery disease. Included in the first phase of the study are patients with small vessels that would require a 2.0 mm stent, which until now, often were untreatable with a DES. Core sizes of the stent will be studied separately.
Read More
